Literature DB >> 1153950

Disease activity and serum proteins in ulcerative colitis. Immunochemical quantitation.

I L Marner, S Friborg, E Simonsen.   

Abstract

Nine different serum proteins from 50 patients suffering from ulcerative colitis were quantitated by means of Laurell's rocket-electrophoresis. The periods of study extended for up to five years. Twenty-six patients were seen at brief intervals from days up to two months; 18 patients were seen at intervals from two to six months. As surgical intervention was urgently required in six cases, few determinations were made in these patients. The disease was classified into five phases according to its clinical activity (as assessed by temperature, blood via the rectum, and number of episodes of diarrhoea). The phases are designated: active febrile; active afebrile; unstable; remission; and restitution. The concentrations of orosomucoid and haptoglobin were found to rise in parallel with intensified clinical activity, while the concentration of pre-albumin falls, thus making these proteins particularly useful for determining changes in the clinical status of the patients. The concentration of pre-albumin during the active phase was especially useful in cases where it was to be decided whether or not surgery was indicated. Concentrations of orosomucoid and IgG were not as useful as pre-albumin in these cases. In patients who escaped operation, the concentration of pre-albumin was seen to rise from low values up to normal before clinical improvement set in.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1153950

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  10 in total

1.  Serum lysozyme in inflammatory bowel and coeliac disease.

Authors:  E Mallas; J M Terry; P Asquith; W T Cooke
Journal:  J Clin Pathol       Date:  1976-07       Impact factor: 3.411

2.  Lamina propria eosinophils and mast cells in ulcerative colitis: comparison between Asians and Caucasians.

Authors:  G F Benfield; R Bryan; J Crocker
Journal:  J Clin Pathol       Date:  1990-01       Impact factor: 3.411

3.  The effects of intravenous pulse methylprednisolone on immunological and inflammatory processes in ankylosing spondylitis.

Authors:  M B Richter; P Woo; G S Panayi; A Trull; A Unger; P Shepherd
Journal:  Clin Exp Immunol       Date:  1983-07       Impact factor: 4.330

4.  [Stress-metabolism after myocardial infarction-demonstrated by means of the behaviour of plasma proteins with short half-life (author's transl)].

Authors:  G Ollenschläger; H Gofferje; L Horbach; H Prestele; K Schultis
Journal:  Klin Wochenschr       Date:  1981-05-04

5.  Is tube feeding with elemental diets a primary therapy of Crohn's disease?

Authors:  H Lochs; M Egger-Schödl; R Schuh; S Meryn; G Westphal; R Pötzi
Journal:  Klin Wochenschr       Date:  1984-09-03

6.  Measurement of serum proteins during attacks of ulcerative colitis as a guide to patient management.

Authors:  N A Buckell; J E Lennard-Jones; M A Hernandez; J Kohn; P G Riches; J Wadsworth
Journal:  Gut       Date:  1979-01       Impact factor: 23.059

7.  Impact of Low Immunoglobulin G Levels on Disease Outcomes in Patients with Inflammatory Bowel Diseases.

Authors:  Nicholas Horton; Xianrui Wu; Jessica Philpott; Ari Garber; Jean-Paul Achkar; Aaron Brzezinski; Bret A Lashner; Bo Shen
Journal:  Dig Dis Sci       Date:  2016-09-12       Impact factor: 3.199

8.  Transient IgA and IgM deficiencies are frequent in children with ulcerative colitis.

Authors:  T Klemola; E Savilahti; S Koskimies
Journal:  Eur J Pediatr       Date:  1988-02       Impact factor: 3.183

9.  Acute-phase reactant protein profiles: an aid to monitoring large bowel cancer by CEA and serum enzymes.

Authors:  A M Ward; E H Cooper; R Turner; J A Anderson; A M Neville
Journal:  Br J Cancer       Date:  1977-02       Impact factor: 7.640

10.  Frequency and risk factors of low immunoglobulin levels in patients with inflammatory bowel disease.

Authors:  Tarun Rai; Xianrui Wu; Bo Shen
Journal:  Gastroenterol Rep (Oxf)       Date:  2015-01-30
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.